We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Berenberg Bank analyst Harry Gillis maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

https://www.tipranks.com/news/the-fly/si-bone-price-target-raised-to-20-from-19-at-needham BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a ...

The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and ...